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Key Points 
1. Mice expressing a form of prothrombin with limited activation potential to meizothrombin 
are viable and are reproductively successful. 
2. Meizothrombin directly activates platelets but has diminished positive regulation of 
hemostatic factor activation. 
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Abstract 
Thrombin-mediated proteolysis is central to hemostatic function but also plays a prominent role 
in multiple disease processes. The proteolytic conversion of fII to α-thrombin (fIIa) by the 
prothrombinase complex occurs through two parallel pathways: i) the inactive intermediate, 
prethrombin, or ii) the proteolytically active intermediate, meizothrombin (fIIaMZ). FIIaMZ has 
distinct catalytic properties relative to fIIa, including diminished fibrinogen cleavage and 
increased protein C activation. Thus, fII activation may differentially influence hemostasis and 
disease depending on the pathway of activation. To determine the in vivo physiologic and 
pathologic consequences of restricting thrombin generation to fIIaMZ, mutations were introduced 
into the endogenous fII gene resulting in expression of prothrombin carrying three amino acid 
substitutions (R157A, R268A, and K281A) to limit activation events to yield only fIIaMZ. 
Homozygous fIIMZ mice are viable, express fII levels comparable to fIIWT mice, and have 
reproductive success. Although in vitro studies revealed delayed generation of fIIaMZ enzyme 
activity, platelet aggregation by fIIMZ is similar to fIIWT. Consistent with prior analyses of human 
fIIaMZ, significant prolongation of clotting times was observed for fIIMZ plasma. Adult fIIMZ animals 
displayed significantly compromised hemostasis in tail bleeding assays, but did not demonstrate 
overt bleeding. More notably, fIIMZ mice had two significant phenotypic advantages over fIIWT 
animals: protection from occlusive thrombosis after arterial injury and markedly diminished 
metastatic potential in a setting of experimental tumor metastasis to the lung. Thus, these novel 
animals will provide a valuable tool to assess the role of both fIIa and fIIaMZ in vivo. 
 
Abstract word count: 247 
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Introduction 
The activation of prothrombin (fII) is the penultimate step of hemostasis. Thrombin (fIIa) cleaves 
fibrinogen and directly activates platelets, via protease-activated receptors (PARs).1 However, 
fIIa also controls its own production, via activation of factors V (fV), VIII (fVIII), XI (fXI), and 
protein C.2 Through these targets and others (e.g., fXIII, thrombin-activatable fibrinolysis 
inhibitor), fIIa not only plays a pivotal role in hemostasis, but in other physiologic and pathologic 
processes (e.g., development, inflammation, cancer biology).3-7 Mouse studies have underlined 
the seminal importance of fII, as the genetic elimination of fII is not compatible with life.3,4,8 
Prothrombin activation proceeds through two parallel activation pathways, depending on 
the site of first cleavage by the prothrombinase complex. One pathway features an intermediate 
that is not an active enzyme, prethrombin, while the second pathway is via an active enzyme 
precursor, meizothrombin (fIIaMZ).9-11 FIIaMZ, as an active enzyme, is capable of participating in 
hemostasis and thrombosis, as well as other physiologic processes. FIIaMZ, like fIIa, activates 
fV,12 fVIII,13 and fXI.14 Thus, fIIMZ may contribute to positive feedback of physiologic hemostasis. 
Both human and murine rfIIaMZ demonstrate reduced fibrinogen cleavage capacity.15,16 Further, 
rfIIaMZ from both species demonstrates an increased activation potential for protein C, in the 
presence of thrombomodulin. Thus, fIIaMZ has potentially distinct effects on hemostasis 
regulation from that of the mature fIIa enzyme. At least two described human mutations result in 
a partial limitation of the activation of prothrombin to meizothrombin. Both prothrombin-Dharhan 
(R271H)17 and prothrombin-Barcelona/Madrid (R271C)18-21 limit fII activation to meizothrombin-
like enzymes by removing a cleavage site. For each of the described pedigrees, individuals that 
were heterozygotes did not have a bleeding diathesis, while homozygotes had a mild to 
moderate bleeding tendency. Thus, while limitation of fII activation has a clear hemostatic effect, 
the broader biologic impact of meizothrombin in vivo has not been defined. The fact that the 
spontaneous human mutations were viable in a homozygous state supports the feasibility for 
examining meizothrombin in a homozygous state in mice. 
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 To better understand the biology of fII overall, and fIIaMZ, specifically, we generated a 
mouse with knock-in targeted mutations in the endogenous F2 allele resulting in three amino 
acid substitutions (R157A, R258A, and K281A) that lock fII after activation by factor Xa (fXa) to 
meizothrombin. These mutations in murine fII have previously been identified to limit activation 
to meizothrombin.16 The working hypothesis was that mice expressing a form of fII that is limited 
to activation to fIIaMZ, would i) be viable without spontaneous hemorrhage, ii) allow examination 
of the role of fIIaMZ in hemostasis in vivo, and iii) provide a novel tool for study of the biology of 
prothrombin in physiologic and pathologic conditions.  
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Methods 
Generation of fIIMZ gene-targeted mice 
For details of the generation of fIIMZ gene-targeted mice, please see the online supplemental 
methods. Mice that are heterozygous for the fII null allele (fII+/-) and compound heterozygotes 
for the conditional fII allele and fII null (fIIlox/-) were previously described.8 In vivo and ex vivo 
(i.e., PT, aPTT and quantitative PCR) experiments utilized outbred hybrid (129/Ola:C57/Bl6) 
littermate controls, except as noted using at least six generations inbred C57/Bl6 animals. All 
experiments were approved by the Cincinnati Children’s Hospital Research Foundation Animal 
Care and Use Committee and complied with National Institutes of Health guidelines. 
 
Hematological profile, determination of prothrombin levels, thrombin generation 
assay, and bleeding times 
For details of the hematologic analysis, please see the online supplemental methods.  
 
Prothrombin activation assay 
For the prothrombin activation assay, citrated PPP was diluted 1:10 with sterile TBS. The 
peptide Gly-Pro-Arg-Pro (EMD Millipore) was added to a final concentration of 4 mM to prevent 
fibrin polymerization. Thromboplastin (Diapharma), reconstituted in sterile water, was added to 
the plasma. Aliquots were taken from this solution and directly added to SDS sample buffer to 
stop the reaction, at time points as indicated in the results section. Immunoblots of these 
samples were performed under reducing conditions, using an antibody specific for the N-
terminus of prothrombin (antigen was a peptide within the first 50 amino acids of prothrombin, 
sc-23340, Santa Cruz Biotechnology). Detection would yield, in decreasing size, intact 
prothrombin, F1.2.A, F1.2, or F1.  
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Thromboplastin-induced platelet aggregation and clot retraction  
Please see the online supplemental methods. 
 
Real-time analysis of in vivo thrombus formation by intravital microscopy 
Cohorts of fIIWT and fIIMZ mice were infused with genotype controlled fluorescently-labeled 
platelets. Anesthetized animals then had mesenteric arterioles isolated and 10% topical ferric 
chloride solution was applied for 5 minutes. An observer blinded to genotype monitored vessels 
for the time to the first thrombus formation and the time until occlusion or for thirty minutes. 
 
Lipopolysaccharide challenge and activated protein C levels 
Please see the online supplemental methods. 
 
Histopathology 
Tissues were fixed in 10% buffered Formalin (Sigma) and embedded in paraffin. Sections were 
cut and subsequently stained with haemotoxylin and eosin (Sigma), Masson’s Trichrome, or 
Prussian Blue (Electron Microscopy Services). Photomicrographs were captured using an 
Axioplan 2 microscope (Zeiss) equipped with an AxiocamHR camera and software (Axiovision 
5.6.3; Zeiss). 
 
Experimental Tumor Metastasis 
As described,22 a single cell suspension of 4 x 105 GFP-expressing Lewis lung carcinoma cells 
(LLCGFP) was injected intravenously in cohorts of C57/Bl6 fIIWT and fIIMZ mice in parallel. 
Fluorescent pulmonary metastatic foci were evaluated 14 days after injection. For B16 
melanoma experimental metastases, a single cell suspension was injected (8 x 104 cells) 
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intravenously into cohorts of C57/Bl6 fIIWT, fIIMZ, and fII+/- mice in parallel, as previously 
described.23 Nineteen days after injection, lungs were removed, stained overnight in picric acid 
solution (Sigma), and metastatic foci counted.   
 
Statistical analysis 
All statistical analyses were generated using the Mann-Whitney U test, except as follows: the χ2 
test was utilized to analyze breeding data and the Fisher’s exact test was utilized to analyze the 
tail bleeding times and percent occlusion in intravital microscopy experiments. Statistical 
analyses were performed on GraphPad Prism version 5.04 (GraphPad Software). 
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Results 
Mice carrying the fIIMZ allele 
To determine the in vivo consequences of expressing a form of prothrombin incapable of 
activation beyond the intermediate, meizothrombin, we introduced three amino acid 
substitutions into the endogenous allele, to remove both a fXa cleavage site and potential fIIa 
auto-cleavage sites: R157A, R268A, and K281A (Figure 1A).24 The R157A and R268A cleavage 
site mutations have been previously identified to limit murine prothrombin activation to 
meizothrombin.16 In addition to these three amino acid changes, we introduced a novel BamHI 
endonuclease site in Exon 7 and a novel EcoRI site in Exon 8, without further modification of the 
amino acid coding sequence. Founder mice transmitted the mutant allele through the germline 
to yield mice heterozygous for the mutation (fIIMZ/WT). Analyses of intercrosses of fIIMZ/WT mice 
resulting in over 800 progeny revealed an approximate 50% decrease in the numbers of 
homozygous mutant animals (hereafter referred to as fIIMZ) relative to what would be expected 
based on a 1:2:1 Mendelian ratio (Table 1). Further studies were conducted to confirm the 
timing of failure of the homozygous animals. Analyses of embryos harvested at embryonic day 
18.5 (E18.5; i.e., the day prior to birth) from fIIMZ/WT breeding pairs did not reveal a significant 
difference in relative numbers of fIIWT and fIIMZ embryos (Table 2). This suggests the loss of 
homozygous fIIMZ animals occurs in the early postnatal timeframe. Consistent with this 
conclusion, evidence of abdominal hemorrhage in fIIMZ pups was observed (Supplemental 
Figure 1). Homozygous fIIMZ mice identified at weaning survived well into adulthood without 
excess mortality. Of the over 200 adult fIIMZ mice generated to date, none were found to suffer 
overt hemorrhage. Furthermore, homozygous fIIMZ females were capable of carrying litters to 
term, with 23 C57Bl/6 homozygous fIIMZ females successfully carrying 52 litters to term.   
Prothrombin expression levels were determined to confirm that homozygous fIIMZ 
neonates had normal leves of circulating fII protein. Total RNA, harvested from fIIWT and fIIMZ 
livers, revealed no significant difference in fII mRNA in either fIIWT or fIIMZ mice, while the 
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expected decreases in mRNA levels for both fII+/- and fIIlox/- control samples were observed 
(Figure 1B). Immunoblot analyses of plasma obtained from fIIWT and fIIMZ homozygous animals 
revealed no discernible differences in fII protein levels between genotypes (Figure 1C). Citrated 
plasma was also assayed for chromogenic fII activity, as it has been previously determined that 
both α-thrombin and meizothrombin have similar affinities for S-2238 chromogenic substrate.16 
After activation of the fII in the plasma samples by ecarin, a similar level of chromogenic activity 
was observed between fIIWT and fIIMZ plasma samples (Figure 1D).   
  To confirm that the prothrombin generated from the fIIMZ animals was indeed limited to 
activation potential to meizothrombin, diluted plasma (1:10 with TBS) from fIIWT and fIIMZ animals 
was incubated with thromboplastin. Fibrin polymerization was blocked with the peptide Gly-Pro-
Arg-Pro. Immunoblots (under reducing conditions) were performed using an antibody against an 
epitope at the N-terminus of the prothrombin molecule. Figure 2A details the expected 
fragments from fII activation in both fIIWT and fIIMZ plasma. Samples from fIIWT animals revealed 
that a fragment consistent with activation to meizothrombin (fragment 1.2.A), that then migrated 
to a size consistent with fragment 1.2 over time (Figure 2B). However, in fIIMZ animals, no 
conversion beyond fIIaMZ was detected (only fragment 1.2.A was present), even after incubation 
for thirty minutes at 37ºC (Figure 2C).  
 
Hematologic analysis of fIIMZ animals 
CBC analyses, on blood from fIIWT and fIIMZ mice, revealed no significant difference in the white 
blood cell count (WBC), hemoglobin, or platelet count (Table 3) between genotypes. 
Additionally, analysis of the WBC differential revealed no significant difference between fIIWT 
and fIIMZ animals (data not shown) in terms of leukocyte subsets. Standard coagulation function 
analyses revealed a significant prolongation of both the PT and aPTT for fIIMZ animals 
compared to fIIWT animals (Table 3). This prolongation was expected given the known 
diminution of fIIaMZ activity for fibrinogen. Predictably, there was no difference in the thrombin 
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times between fIIWT and fIIMZ mice (Table 3) consistent with fIIMZ having no impact on plasma 
fibrinogen levels.    
 Comparative thrombin generation assays (TGA) were performed on plasma from both 
fIIMZ and fIIWT mice (representative curves, Figure 3A-B). The fIIMZ animals had both a prolonged 
lag time compared to fIIWT [e.g., a prolonged time to any (meizo)thrombin generation, (Figure 
3C)] and a prolonged time to peak (meizo)thrombin production (Figure 3D). Furthermore, peak 
(meizo)thrombin production and area under the curve were found to be reduced in fIIMZ 
compared to fIIWT mice (Figure 3E-F, respectively). The Velocity Index, the rate of 
(meizo)thrombin generation, was also decreased in fIIMZ mice in contrast to fIIWT animals (data 
not shown). 
 To explore the contribution of fIIMZ toward activated protein C (aPC) generation, we 
challenged cohorts of fIIMZ and fIIWT mice with LPS, an inflammatory challenge known to activate 
the hemostatic cascade and result in aPC generation. Two hours after administration of LPS, 
fIIWT mice displayed the expected, and statistically significant, increase in aPC activity 
(Supplemental Figure 2). The fIIMZ animals challenged with LPS did not display a significant 
difference in aPC activity compared to unchallenged fIIMZ animals. Interestingly, there was also 
not a statistically significant difference in aPC generation between the fIIMZ and fIIWT mice after 
LPS.  In light of the data regarding reduced meizothrombin generation in fIIMZ animals, these 
data do not necessarily contradict the previously reported findings regarding activity of fIIaMZ for 
PC; this finding would also be expected with diminished overall fIIaMZ activity secondary to 
diminished generation of fIIaMZ from fIIMZ.  
 
Meizothrombin induced platelet aggregation and clot retraction 
FIIa is a potent activator of platelet aggregation through activation of PARs.1 To determine the 
potential of fIIaMZ to activate platelets, we initiated fIIa or fIIaMZ generation in platelet-rich plasma 
(PRP) derived from fIIWT and fIIMZ animals. Qualitative platelet aggregation was comparable 
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between genotypes, with similar total aggregation (Figure 4A-B; fIIWT n=7, fIIMZ n=7). However, 
there was a prolonged time to both shape change and positive deflection in fIIMZ animals (Figure 
4C-D). We postulate that the prolonged time to initiation of platelet aggregation in fIIMZ plasma 
was a function of the extended time to (meizo)thrombin generation. More notably, these data 
suggest that murine fIIaMZ is capable of activating PAR-4. 
Clot retraction is an important physiologic step in both hemostasis and wound repair that 
is dependent on fibrin polymer formation, platelet activation, and factor XIII (fXIII) activity.25-27 To 
directly determine if fIIMZ supports clot retraction, we initiated coagulation with thromboplastin in 
both whole blood and platelet-rich plasma (platelet counts adjusted to 2.5 x 105 platelets/µL) 
from fIIWT and fIIMZ animals. While time to initial clot retraction was modestly delayed in fIIMZ 
blood and plasma samples, both fIIWT and fIIMZ displayed evidence of similar maximal clot 
retraction in both whole blood and platelet rich plasma (Supplemental Figure 3A-B; E-F). There 
was no qualitative difference in the size of clots by the end of the 1.5 hour observation period. 
Further, red blood cell (RBC) inclusion in thrombi was not significantly different between 
samples from fIIWT and fIIMZ mice (Supplemental Figure 3C-D). 
 
 
In vivo hemostasis and thrombosis assessment 
To determine the effect of limiting fII activation to meizothrombin on hemostasis in vivo, we 
employed a standard tail tip amputation assay. Cohorts of fIIMZ and fIIWT animals were 
challenged by amputation of 3 mm of the distal tail. All fIIWT mice had cessation of bleeding, with 
a mean time to cessation of 72 ± 6 s. However, all fIIMZ animals had bleeding for the entire ten-
minute observation period (Figure 5A). Qualitative narrowing of the caliber of the blood stream 
from the amputation site was sometimes observed in fIIMZ animals, but bleeding universally 
persisted despite throughout the observation period. 
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 In order to define thrombotic potential in FIIMZ mice, we challenged FIIMZ and fIIWT mice in 
parallel with a ferric chloride mesenteric artery injury. Here, fluorescein-labeled platelets from 
donor mice of the same genotype as the challenged animals were infused prior to the procedure 
to allow real-time tracking of thrombus size and time to occlusion by intravital fluorescent 
microscopy. FIIWT mice demonstrated rapid formation of platelet aggregates that progressed 
steadily to full occlusion (Figure 5B). While fIIMZ animals had clear evidence of platelet 
aggregation (Figure 5C), fIIMZ mice demonstrated a significantly increased time to first thrombus 
formation and prolonged time to occlusion relative to fIIWT mice, with a significant fraction of fIIMZ 
mice failing to form a stable occlusive thrombus during the 30-minute observation period 
(Figures 5D & E). In evaluation of the formation of thrombosis in the fIIMZ animals, the thrombi 
formed after ferric chloride injury were unstable with frequent emboli. In mice with no occlusive 
thrombi, a combination of delayed thrombus formation and embolization contributed to this 
phenotype (Supplemental video 1 represents fIIWT animals and video 2 represents fIIMZ animals). 
Taken together with the platelet aggregation data, these data suggest the hypothesis that 
diminished fibrin polymer formation in fIIaMZ mice results in a failure to stabilize the growing 
platelet aggregate and a corresponding protection from arterial occlusion. 
 
FIIMZ animals develop cardiac fibrosis 
Mice with genetic deficiencies of TF, fII, fVII, fX, and fXIII8,28-31 develop cardiac hemorrhage with 
iron deposition and subsequent fibrosis that progresses with age. To investigate if fIIMZ 
predisposes adult animals to spontaneous hemorrhage, we examined organs from cohorts (10-
12 weeks of age) of C57/Bl6 fIIWT and fIIMZ mice. No gross or microscopic evidence of 
hemorrhage was observed in the pulmonary, gastrointestinal, genitourinary, or central nervous 
systems of fIIWT or fIIMZ animals. As expected, fIIWT mice did not show any histologic evidence of 
cardiac pathologies (Figure 6A-C). In contrast, cardiac fibrosis was readily identified in both 
male and female fIIMZ mice (Figure 6D-E) and was most notable in the sub-epicardial zones. 
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Prussian Blue staining of the heart tissue revealed co-localization of iron deposits with areas of 
fibrosis (Figure 6F), suggesting chronic hemorrhage leading to the etiology of fibrosis in this 
setting.  
Additionally, cohorts of inbred C57/Bl6 fIIWT and fIIMZ mice were aged for a year prior to 
having organs harvested. Notably, no loss of fIIMZ animals occurred during this time. Grossly, 
evidence of one ovarian hemorrhagic cyst and one intestinal hemorrhage were noted in the fIIMZ 
(n=8) animals. There was no evidence of gross or microscopic hemorrhage in the fIIWT (n=7) 
mice (Supplemental Figure 4A-C). Abundant cardiac fibrosis was noted in both male and female 
fIIMZ animals (Supplemental Figure 4D-E), whereas minimal, if any, cardiac fibrosis was noted in 
the fIIWT mice. Again, sites of fibrosis co-localized with sites of iron deposition (Supplemental 
Figure 4F), likely due to local hemorrhage. There were no hemorrhagic findings in other organ 
systems.  
 
FIIMZ mice have diminished experimental metastases 
To investigate the biologic consequences of fIIMZ activity in a disease context distinct from a 
classical hemostasis or thrombosis challenge, we examined the contribution of fIIMZ to 
experimental tumor metastasis. FIIa can support metastasis through tumor cell-instrinsic 
mechanisms involving activation of PARs,32 as well as through fibrinogen cleavage and platelet 
activation.23,33,34 Our hypothesis was that fIIMZ animals would demonstrate reduced numbers of 
metastases. Cohorts of inbred C57Bl/6-derived fIIMZ and fIIWT mice were intravenously injected 
in parallel with LLCGFP cells and the lungs harvested 14 days later. While abundant metastases 
were uniformly present among the fIIWT animals, few, if any, fIIMZ animals had any evidence of 
metastatic foci (Figure 7A-C). This was similar to previous findings of LLC experimental lung 
metastases in animals with lowered levels of prothrombin.35 To expand on these findings and 
further compare fIIMZ to diminished levels of prothrombin, we compared experimental 
metastases of B16 melanoma in fIIWT, fIIMZ, and fII+/- animals. Again, fIIMZ animals demonstrated 
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a significant protection from the development of lung metastases (Figure 7D; F-G). Evaluation of 
tumor metastases in mice with 50% prothrombin (fII+/-) revealed an essentially identical pattern 
to fIIMZ animals (7E). This suggests that even modest diminutions in thrombin generation 
potential, either through diminution of circulating prothrombin levels or alteration of activation, 
have profound effects on metastatic potential of tumor cells.  
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Discussion 
Activation of thrombin follows one of two pathways, which produce functionally different 
intermediate species. The intermediate of the alternative prothrombin activation pathway 
prethrombin, lacks detectable protease activity. In contrast, meizothrombin, a short-lived 
activation intermediate of prothrombin,9,11 has readily detectable protease activity with notably 
distinct substrate specificities from α-thrombin. The pathway of thrombin activation is dictated in 
part by the microenvironment or cellular surface on which the prothrombinase complex is 
assembled. Recent data have suggested that thrombin generation on platelets primarily 
proceeds via prethrombin36 whereas thrombin generation on the surface of RBCs tends to occur 
through meizothrombin37. While it has been hypothesized that the pathway of fII activation is 
biologically relevant, given the short half-life of fIIaMZ, the specific contribution of fIIaMZ-mediated 
proteolysis to hemostasis and other physiologic or pathologic processes has been difficult to 
assess in vivo. Here, we demonstrate for the first time the consequences of limiting the 
activation of endogenous fII to an activation intermediate in vivo. Mice that express fIIMZ are 
viable, survive well into adulthood, and have reproductive success. FIIMZ mice have partial 
perinatal lethality, unlike fIIlox/- animals (mice with 10% of wildtype prothrombin levels). Similar to 
fIIlox/- animals, fIIMZ animals that survive to weaning have an essentially normal lifespan. FIIMZ 
animals have significantly delayed and decreased (meizo)thrombin generation, compared to 
fIIWT mice. FIIMZ animals also have delayed time to occlusion following a ferric chloride arterial 
injury and prolonged bleeding times.  
While we did not directly measure factor XIII (fXIII) activation by fIIMZ, indirect evidence 
points to at least adequate activation. Clot retraction in fIIMZ plasma was normal, both in platelet-
rich plasma and in whole blood. FXIII activity is required in the process of clot retraction and 
RBC retention within the thrombus.25-27 As additional evidence that fIIMZ activates fXIII, RBC 
retention in whole blood thrombi after clot retraction was not significantly different between fIIWT 
and fIIMZ animals. Similarly, PAR-1 activation by fIIMZ has not been directly measured. However, 
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the homozygous fIIMZ animals do not have the mid-gestation loss seen in PAR-1-38 and fII- 
animals,3,4 which would suggest that activation of PAR-1 by fIIaMZ is adequate to support 
successful embryonic development.  
 Both human and murine rfIIaMZ have decreased polymerization potential of fibrin.15,16 Our 
findings with in vivo fIIMZ are compatible with these results. Prolongation of the PT and aPTT are 
both suggestive of a decreased polymerization of fibrin (the endpoint of both assays). While 
delayed, fIIaMZ also induces platelet aggregation qualitatively similar to α-thrombin. However, 
fIIMZ animals were unable to achieve hemostasis after a standard tail amputation bleeding time. 
This is in contrast to animals expressing a form of fibrinogen that cannot be cleaved by thrombin 
(FibAEK). FibAEK mice demonstrated partial cessation of bleeding in a standard tail amputation 
bleeding time.39 This suggests that while inadequate fibrin polymerization contributes to 
abnormal hemostasis in fIIMZ mice, positive feedback for self-activation also likely participates in 
the failure to achieve hemostasis.  
Intravital microscopy, following mesenteric arteriole ferric chloride injury, also reveals 
insight into the failure to form thrombi. While fIIMZ
 
animals formed platelet aggregates at the site 
of vessel injury, these aggregates were not stable. The aggregates formed after ferric chloride 
injury in the fIIWT controls quickly evolved into occlusive thrombi. In stark contrast, fully occlusive 
thrombi never formed in fIIMZ mice, rather smaller aggregates embolized from the initial 
thrombus in fIIMZ animals precluding occlusion. Taken together, this suggests in the setting of 
animals expressing only fIIMZ, platelet aggregation is adequate, but insufficient positive feedback 
to the hemostatic cascade and diminished fibrinogen cleavage lead to unstable platelet 
aggregates. Thus, a lack of both physiologic hemostasis and diminished thrombosis is observed 
in fIIMZ mice. 
 Previous studies have reported the effects of recombinant human and murine 
meizothrombin (rhfIIaMZ and rmfIIaMZ, respectively), both in vitro and in vivo.16,40-42 Similar to our 
current work, rmfIIaMZ demonstrated significantly diminished fibrinogen cleavage capabilities in 
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vitro. However, in the same in vitro studies of rmfIIaMZ, increased protein C activation in the 
presence of thrombomodulin was observed.16 Our data suggest that the activation of protein C 
is not significantly different in the fIIMZ and fIIWT animals after an LPS challenge. Direct 
comparison between the in vitro findings and the in vivo analysis of aPC generation reported 
here is complicated by the overall reduced activation potential of meizothrombin in the 
homozygous mutant mice. Thus, we cannot further address the activity of fIIaMZ for protein C.   
The other significant difference in the published account of rmfIIaMZ and our current findings 
using knock-in animals is that rmfIIaMZ was evaluated not as a zymogen, but as a fully active 
enzyme. Here, we were able to explore the consequences of limiting all activation of fII to 
meizothrombin. While in vitro data suggested that rhfIIaMZ would be capable of positive 
feedback of the hemostatic cascade, our data in murine meizothrombin suggest otherwise.12,13 
Further studies will be needed to assess the in vivo activation of factors V, VIII, and XI by 
meizothrombin. As (meizo)thrombin generation is significantly altered in the fIIMZ compared to 
fIIWT animals, this suggests meizothrombin is less effective at supporting activation of at least 
one of these factors. Our data challenges the hypothesis that fIIaMZ contributes to physiologic 
hemostasis.  
 Another modification of fII leading to a specificity difference, fIIWE, has diminished 
fibrinogen cleavage while preserving activation of protein C.43,44 Exploiting this difference in 
specificities, fIIaWE has been administered pharmaceutically as an anticoagulant43,45 and anti-
inflammatory46 agent. Additionally, animals have been generated that express only the fIIWE 
zymogen.5 However, unlike the fIIMZ animals, mice expressing only fIIWE are not viable. The 
difference in viability between fIIWE and fIIMZ animals illustrates that fIIMZ does not impact 
physiologic hemostasis to the same degree. Further, fIIMZ animals may have an advantage in 
studying fII specificity alterations in physiologic or disease states. 
 Animals expressing fIIMZ developed cardiac fibrosis, worsening with age, similar to mice 
with low levels of tissue factor, fII, fVII, fX, and fXIII.8,28-31 Areas of fibrosis co-localized with 
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areas of iron deposition, likely related to recurrent small hemorrhages. Unlike mice with low 
levels of fII (both fIIlox/- mice and transgenic mice expressing low levels of human prothrombin) 
that only develop modest cardiac fibrosis at over one year of age,8 fIIMZ mice developed 
substantial cardiac fibrosis by 8-10 weeks of age. Also unlike previous accounts of cardiac 
fibrosis hemostatic factor deficiencies, we did not observe a gender predisposition to the 
development of cardiac fibrosis. Thus, while (meizo)thrombin-induced platelet aggregation is 
preserved, this was not sufficient to prevent the cardiac parenchymal bleeding that leads to 
cardiac fibrosis. That this bleeding is limited to the heart, as opposed to bleeding patterns seen 
in the low TF and low fVII animals, suggest tissue differences in hemostasis requirements to 
prevent hemorrhagic complications.47   
 As proof of concept that fIIMZ animals will provide a novel tool to study the biology of fII in 
disease, we examined the effect of limitation of the activation of fII in the setting of tumor 
metastasis. We found that mice with fIIMZ have dramatically reduced experimental metastasis 
compared to fIIWT animals. This was not necessarily a predictable result, since fibrin(ogen) and 
platelets both contribute to early protection of metastatic foci via protection from natural killer 
cells.23,33 FIIMZ retains, albeit reduced, fibrinogen cleavage potential, and essentially normal 
platelet activation capacity. That mice with fIIMZ had very few metastases is most likely related to 
the low positive feedback in generation of (meizo)thrombin combined with diminished fibrinogen 
cleavage and polymerization and a delay in platelet activation. However, other possible 
mechanisms cannot be excluded, such as diminished PAR activation in either tumor cells or 
non-malignant stromal cells. Interestingly, fII+/- animals displayed a similar phenotype in tumor 
metastasis. FII+/- animals have approximately 75% of peak thrombin generation seen in fII+/+ 
mice.5 Protection from metastases in fIIMZ and fII+/- underscores that tumor metastasis is quite 
sensitive to derangements in thrombin generation. 
The current studies demonstrate that mice expressing only fIIMZ have adequate 
hemostasis for successful survival and reproduction and that these animals provide a unique 
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tool to further assess the role of both prothrombin and meizothrombin in physiologic and 
pathologic processes. As coagulation factors are more closely tied to non-hemostatic 
processes, the ability to study altered enzyme specificity in vivo will allow further elucidation of 
the mechanistic contribution of fII to disease. Tools, such as fIIMZ animals, will be crucial to 
determine how the activation and activity of fII modify disease severity. 
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Figure Legends 
 
Figure 1. Alteration of the endogenous fII allele to limit activation to meizothrombin. (A) This 
map demonstrates the targeting vector used to alter the endogenous fII allele as well as a map 
of the endogenous allele. Incorporation of the targeting vector by homologous recombination 
targeting vector was confirmed in germline-competent mice by PCR.  After transmission of the 
targeted allele by the chimeric animals, mice were crossed with CMV-Cre animals to remove the 
HPRT cassette, with the final targeted allele as illustrated. Loss of the HPRT cassette was also 
confirmed by PCR. (B) Liver fII mRNA levels in fIIWT and fIIMZ animals were assessed using 
qPCR. No significant difference in fII RNA levels were detected between the two genotypes. In 
contrast, significant decreases, as expected, were noted in fII+/- and fIIlox/- animals (n = 6 in all 
cohorts). (C) Plasma from both fIIMZ and fIIWT mice was assayed for fII antigen levels via 
Western blot. No difference in fII levels between fIIWT and fIIMZ animals was appreciable on the 
immunoblot. (D) Chromogenic fIIa activity from both fIIWT and fIIMZ  plasma was assayed 
following activation with ecarin. There was no significant difference in plasma fIIa activity 
derived from either fIIMZ or fIIWT animals (n = 7 in both cohorts). The expected decrease in fIIa 
activity in both fII+/- and fIIlox/- (n = 4 in both cohorts) was readily detectable.   
 
Figure 2. Evaluation of activation and activity of fIIMZ. (A) Schematic of prothrombin cleavage 
sites. An antibody was utilized that targets the N-terminus of prothrombin and the immunoblot 
was performed under reducing conditions. Therefore, an activation event resulting in 
meizothrombin would result in a product including fragment 1.2 (F1.2) and the A chain (F1.2.A). 
Upon further cleavage to α-thrombin, F1.2 is released from the A chain. (B-C) Activation of 
prothrombin was determined in both fIIWT and fIIMZ animals. Hemostatic factor activation was 
initiated with thromboplastin in plasma from fIIWT (B) and fIIMZ (C) animals. Aliquots were taken 
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at specified time points and assayed via immunoblot for fII and products of fII activation. While 
no remaining detectable fII or fragment 1.2.A is present in the fIIWT samples beyond 30 seconds, 
prothrombin from the fIIMZ animals remains at F1.2.A (representing meizothrombin) throughout 
the time period assayed. No further conversion/degradation was detected.  
 
Figure 3. Determination of the activation of fII in fIIWT and fIIMZ plasmas. To evaluate the 
activation potential of fII in either fIIWT or fIIMZ plasma, we utilized thrombin generation assays to 
assess fIIa/fIIaMZ generation over time. Representative thrombin generation curves from fIIWT (A) 
and fIIMZ (B) plasma. Time to the start of thrombin generation was significantly delayed in fIIMZ 
plasma (C), as well as time to peak thrombin generation (D). Peak fIIa/fIIaMZ generation was 
also significantly decreased in the fIIMZ animals (E). Of note plasma from four fIIMZ animals did 
not have any appreciable (meizo)thrombin generation. Therefore, they were excluded from the 
time to peak (meizothrombin) analysis. Total fIIa/fIIaMZ generation, as represented by area 
under the curve, was also significantly reduced in fIIMZ plasma compared to fIIWT plasma (F).  
 
Figure 4. Platelet aggregation in fIIMZ animals. Platelet aggregation in PRP derived from either 
fIIWT or fIIMZ animals in response to thromboplastin was determined. Fibrin polymerization was 
blocked with Gly-Pro-Arg-Pro. There was no qualitative difference between fIIWT and fIIMZ 
platelet aggregation (A and B, respectively). However, a modest, but statistically significant 
difference was noted in time to shape change (as determined by negative deflection, C) and 
time to positive deflection (D).  
 
Figure 5. Impaired hemostasis and thrombus formation in fIIMZ animals. A. In a standard tail 
bleeding time analysis, fIIWT animals all achieved hemostasis, while no fIIMZ mice had cessation 
of bleeding during the 10 minute window of evaluation. In ferric chloride mesenteric arteriole 
injury, fIIWT animals developed occlusive thrombi (B). However, while fIIMZ mice formed platelet 
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aggregates, these were unstable and embolized, frequently without progression to occlusion of 
the vessel (C). FIIMZ animals also exhibited a prolonged time to first thrombus formation (D) and 
prolonged time to occlusion (E).  
 
Figure 6. Cardiac fibrosis in fIIMZ mice. FIIWT mice did not have any evidence of cardiac fibrosis 
or hemorrhage/iron deposition (A-C). However fIIMZ animals developed evidence of cardiac 
fibrosis by the age of 10 weeks on both H & E and trichrome stains (D-E). At 10 weeks of age, 
the most pronounced area of fibrosis was in the subepicardial region. Areas of fibrosis co-
localize with areas of iron deposition as shown here on Prussian blue stain (F). All scale bars 
represent 100 microns.  
 
Figure 7. Diminished experimental tumor metastasis in fIIMZ animals. Cohorts of fIIWT and fIIMZ 
animals were challenged with an IV bolus of LLCGFP. Two weeks later, metastatic foci in the lung 
were determined. A substantial, statistically significant diminution in the number of lung 
metastases was noted in the fIIMZ animals compared to fIIWT mice (A). FIIWT animals had 
prominent metastatic foci (B), while many fIIMZ animals demonstrated few, if any, metastases 
(C). Cohorts of fIIWT and fIIMZ animals were challenged with IV bolus of B16 melanoma. Eighteen 
days later, metastatic foci in the lung were determined. As was seen with LLC,  fIIMZ animals 
had significantly fewer metastatic foci when compared to fIIWT mice (D). The same pattern was 
found when comparing fIIWT mice to mice with 50% prothrombin (fII+/-) (E). Numerous metastatic 
foci were seen in fIIWT animals (F), while metastases were rare in fIIMZ mice (G). 
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